Objective: To observe the role of venomous hemocoagulase combined with pituitrin in patients with hemoptysis treated with transcatheter arterial embolization. Methods: From May 2017 to December 2019, 120 patients with hemoptysis treated by bronchial artery embolization were divided into an observation group and a control group according to random digital table method (n=60 for each group). The control group was given intravenous drip of pituitary, and the observation group was given snake venom hemocoagulase on the basis of the control group. The therapeutic effect, coagulation function, and safety of the 2 groups were compared. Results: The total effective rate of treatment in the observation group was significantly higher than that in the control group (P<0.05). There was no significant difference in the levels of prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) between the two groups before treatment (all P>0.05). The levels of PT, APTT, and TT in the 2 groups were significantly lower than those before treatment (all P<0.05). The levels of PT, APTT, and TT in the observation group were significantly lower than those in the control group (all P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P<0.05). Conclusion: Venomous hemocoagulase combined with pituitary hindleaf can effectively improve the efficacy of hemoptysis patients treated by transbronchial embolization, and reduce the recurrence rate with high safety.